1. Market Research
  2. > Tachycardia (Tachyarrhythmias) - Pipeline Review, H2 2013

Tachycardia (Tachyarrhythmias) - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 33 pages

Tachycardia (Tachyarrhythmias) - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Tachycardia (Tachyarrhythmias) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Tachycardia (Tachyarrhythmias), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tachycardia (Tachyarrhythmias). Tachycardia (Tachyarrhythmias) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Tachycardia (Tachyarrhythmias).
- A review of the Tachycardia (Tachyarrhythmias) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Tachycardia (Tachyarrhythmias) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Tachycardia (Tachyarrhythmias).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Tachycardia (Tachyarrhythmias) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Tachycardia (Tachyarrhythmias) - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Tachycardia (Tachyarrhythmias) Overview 6
Therapeutics Development 7
Pipeline Products for Tachycardia (Tachyarrhythmias) - Overview 7
Pipeline Products for Tachycardia (Tachyarrhythmias) - Comparative Analysis 8
Tachycardia (Tachyarrhythmias) - Therapeutics under Development by Companies 9
Tachycardia (Tachyarrhythmias) - Therapeutics under Investigation by Universities/Institutes 10
Tachycardia (Tachyarrhythmias) - Pipeline Products Glance 11
Clinical Stage Products 11
Tachycardia (Tachyarrhythmias) - Products under Development by Companies 12
Tachycardia (Tachyarrhythmias) - Products under Investigation by Universities/Institutes 13
Tachycardia (Tachyarrhythmias) - Companies Involved in Therapeutics Development 14
Aop Orphan Pharmaceuticals AG 14
Tachycardia (Tachyarrhythmias) - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Assessment by Therapeutic Class 23
Drug Profiles 25
landiolol - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
acetazolamide sodium - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
atomoxetine hydrochloride - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
entacapone - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
mecamylamine hydrochloride - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Tachycardia (Tachyarrhythmias) - Dormant Projects 30
Tachycardia (Tachyarrhythmias) - Product Development Milestones 31
Featured News and Press Releases 31
Nov 22, 2013: Approval for Additional Indication of Onoact 50 for injection, Short-Acting Selective ß1 Blocker in Japan 31
Feb 20, 2013: Ono Pharma Submits Additional Indication Application For Onoact 50 In Japan 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33



List of Tables

Number of Products under Development for Tachycardia (Tachyarrhythmias), H2 2013 7
Number of Products under Development for Tachycardia (Tachyarrhythmias) - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Products under Development by Companies, H2 2013 12
Products under Investigation by Universities/Institutes, H2 2013 13
Tachycardia (Tachyarrhythmias) - Pipeline by Aop Orphan Pharmaceuticals AG, H2 2013 14
Assessment by Monotherapy Products, H2 2013 15
Number of Products by Stage and Target, H2 2013 17
Number of Products by Stage and Mechanism of Action, H2 2013 19
Number of Products by Stage and Route of Administration, H2 2013 21
Number of Products by Stage and Molecule Type, H2 2013 22
Number of Products by Stage and Therapeutic Class, H2 2013 24
Tachycardia (Tachyarrhythmias) - Dormant Projects, H2 2013 30



List of Figures

Number of Products under Development for Tachycardia (Tachyarrhythmias), H2 2013 7
Number of Products under Development for Tachycardia (Tachyarrhythmias) - Comparative Analysis, H2 2013 8
Comparative Analysis by Clinical Stage Development, H2 2013 11
Assessment by Monotherapy Products, H2 2013 15
Number of Products by Top 10 Target, H2 2013 16
Number of Products by Stage and Top 10 Target, H2 2013 17
Number of Products by Top 10 Mechanism of Action, H2 2013 18
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 19
Number of Products by Top 10 Route of Administration, H2 2013 20
Number of Products by Stage and Top 10 Route of Administration, H2 2013 21
Number of Products by Stage and Top 10 Molecule Type, H2 2013 22
Number of Products by Top 10 Therapeutic Class, H2 2013 23
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 24



Companies Mentioned

Aop Orphan Pharmaceuticals AG

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.